A 14-year-old boy presenting with gradual abdominal distension and occasional abdominal pain for 2 years

Nazmul Hassan, Mahmudul Hasan, Kaniz Fathema, Khondaker Mobasher, Fahmida Begum and Wahiduzzaman Mazumder

Presentation of Case

Dr. Md. Nazmul Hassan (Resident): A 14-year-old boy, 4th issue of his non-consanguineous parents got admitted in the Department with the complaints of gradual abdominal distension and occasional abdominal pain since two years of his age. There was no history of jaundice, upper gastrointestinal bleeding, fever, contact with a known case of tuberculosis patient or family history of such type of illness. On examination, he was alert, anicteric, no facial dysmorphism, vitally stable, no stigmata of chronic liver disease and anthropometrically well thrived. On alimentary system examination, the abdomen was hugely distended, visible engorged vein (Figure 1), hepatomegaly (10 cm), spleen just palpable and huge ascites was present. Other systemic examination revealed no abnormality. Routine laboratory investigations showed hemoglobin was 11.4 g/dL; a total leucocyte count was 6,500 cells/mm³ and among, neutrophils were 44% and lymphocytes 49%. The erythrocyte sedimentation rate was 40 mm in 1st hour and platelet count was 136 × 10⁹/mm³. The liver function tests showed serum albumin (41 g/L), prothrombin time (14.8 sec), international normalized ratio 1.25 and normal alanine aminotransferase level (9 U/L). Serum electrolyte and creatinine levels were also normal. The ascitic fluid examination showed total cell count of 160 cells/mm³ with 10% polymorph nuclear neutrophils and 90% lymphocytes. The biochemical examination showed the protein level was 5.5 g/dL and the sugar level was 5.3 g/dL. The adenosine deaminase level was normal. The serum ascites albumin gradient was high of 1.5 (>1.1). Endoscopy of the upper gastrointestinal tract revealed a developing varix (Figure 2A). Ultrasonography of the abdomen showed hepatosplenomegaly with huge ascites. Color doppler study showed a compressed middle hepatic vein due to enlarged caudate lobe (8.5 x 3.9 cm), loss of normal flow characteristics, hepatofugal flow direction and features of mild portal hypertension but no thrombosis was found. Computed tomography venogram of the liver revealed portal vein was dilated, tortuous and produced varices along with the spleno-portal circulation (Figure 2B). Mantoux test and Chest X-ray were normal. Blood for inherited deficiency revealed a deficiency of protein S and antithrombin III but protein C was normal (Table I).

Provisional Diagnosis

Budd-Chiari syndrome most probably due to inherited thrombophilia (deficiency of protein C, protein S and antithrombin III)

Differential Diagnosis

Dr. Mahmudul Hasan (Resident): As the patient was having a history of gradual abdominal distension and occasionally abdominal pain and on examination hepatosplenomegaly and ascites present, we differentially thought about chronic liver disease.

Dr. Kaniz Fathema (Resident): As Bangladesh is a highly endemic zone for tuberculosis and patient having gradual abdominal distension, occasional abdominal pain along with hepato-
Chiari syndrome is characterized clinically by a triad of ascites, hepatomegaly and right upper quadrant pain. It is an uncommon but important syndrome because of many disorders. It may be associated with several hematologic or malignant diseases. In the late 1800s, the term Budd-Chiari was first named after a British internist, George Budd, described three cases of hepatic vein thrombosis due to abscess-induced phlebitis and in 1899 Austrian pathologist Hans Chiari, added the first pathologic description of a liver with obliterating endophlebitis of the hepatic veins. The prevalence of Budd-Chiari syndrome is 1/100,000 among the general population worldwide. Compared to adults, it is very uncommon in children. Most of the cases of classic Budd-Chiari syndrome occur between the ages of 20 and 39 years and only 5% were found to be below 12 years of age. The syndrome can be classified as: a) Primary (intra-luminal obstruction by a thrombus or web) or b) secondary (extrinsic compression by an abscess, tumor, cyst, or hyperplastic nodules). Clinically, it can be presented as a) Acute- develops usually within 1 month or symptomatic for less than 6 months and characterized by intractable ascites, abdominal pain, liver enlargement, renal failure, elevation of hepatic enzymes and coagulopathy; b) Subacute- which is insidious onset. It may take as long as 3 months to become asymptomatic, usually having minimal/trace or no ascites but do not have esophageal bleeding; c) Chronic- disease duration of 6 or more months or signs of portal hypertension present. For diagnostic evaluation of Budd-Chiari syndrome, the first step is the doppler ultrasonography of the hepatic vessels and inferior vena cava, which in 95% cases establish the diagnosis. In doppler ultrasonography, highly specific findings for Budd-Chiari syndrome are stenosis, thrombosis, fibrotic cord, or insufficient recanalization of the vessel in the hepatic or caval veins, along with caudate lobe hypertrophy.

### Chronic liver disease

**Dr. Hassan**: Chronic liver disease comprises both chronic hepatitis and cirrhosis. Cirrhosis is defined as a diffuse liver process where fibrosis has resulted in a conversion of the liver architecture into structurally abnormal nodules. In children, a wide range of causes of hepatocellular injury present that include causes of cholestasis, infection, toxin, metabolic, vascular, and nutritional disorders that may result in cirrhosis of the liver. Irrespective of the cause of chronic injury, and in the absence of removal of the cause of injury, the cirrhotic state and many complications persist. The diagnosis is based on the combination of clinical (stigmata of chronic liver disease), biochemical (liver function tests) and imaging findings. Unfortunately, available therapies for many chronic liver diseases causing cirrhosis in children are ineffective. The treatment is limited to the management of these secondary pathophysiological complications and liver transplantation is the only available definitive option when the liver failure established.

### Abdominal tuberculosis

**Dr. Fathema**: Disseminated abdominal tuberculosis involves the gastrointestinal tract, peritoneum, mesentery, and in the late 1800s, the term Budd-Chiari was first named after a British internist, George Budd, described three cases of hepatic vein thrombosis due to abscess-induced phlebitis and in 1899 Austrian pathologist Hans Chiari, added the first pathologic description of a liver with obliterating endophlebitis of the hepatic veins. The prevalence of Budd-Chiari syndrome is 1/100,000 among the general population worldwide. Compared to adults, it is very uncommon in children. Most of the cases of classic Budd-Chiari syndrome occur between the ages of 20 and 39 years and only 5% were found to be below 12 years of age. The syndrome can be classified as: a) Primary (intra-luminal obstruction by a thrombus or web) or b) secondary (extrinsic compression by an abscess, tumor, cyst, or hyperplastic nodules). Clinically, it can be presented as a) Acute- develops usually within 1 month or symptomatic for less than 6 months and characterized by intractable ascites, abdominal pain, liver enlargement, renal failure, elevation of hepatic enzymes and coagulopathy; b) Subacute- which is insidious onset. It may take as long as 3 months to become asymptomatic, usually having minimal/trace or no ascites but do not have esophageal bleeding; c) Chronic- disease duration of 6 or more months or signs of portal hypertension present. For diagnostic evaluation of Budd-Chiari syndrome, the first step is the doppler ultrasonography of the hepatic vessels and inferior vena cava, which in 95% cases establish the diagnosis. In doppler ultrasonography, highly specific findings for Budd-Chiari syndrome are stenosis, thrombosis, fibrotic cord, or insufficient recanalization of the vessel in the hepatic or caval veins, along with caudate lobe hypertrophy.

### Chronic liver disease

**Dr. Hassan**: Chronic liver disease comprises both chronic hepatitis and cirrhosis. Cirrhosis is defined as a diffuse liver process where fibrosis has resulted in a conversion of the liver architecture into structurally abnormal nodules. In children, a wide range of causes of hepatocellular injury present that include causes of cholestasis, infection, toxin, metabolic, vascular, and nutritional disorders that may result in cirrhosis of the liver. Irrespective of the cause of chronic injury, and in the absence of removal of the cause of injury, the cirrhotic state and many complications persist. The diagnosis is based on the combination of clinical (stigmata of chronic liver disease), biochemical (liver function tests) and imaging findings. Unfortunately, available therapies for many chronic liver diseases causing cirrhosis in children are ineffective. The treatment is limited to the management of these secondary pathophysiological complications and liver transplantation is the only available definitive option when the liver failure established.

### Abdominal tuberculosis

**Dr. Fathema**: Disseminated abdominal tuberculosis involves the gastrointestinal tract, peritoneum, mesentery, and in the late 1800s, the term Budd-Chiari was first named after a British internist, George Budd, described three cases of hepatic vein thrombosis due to abscess-induced phlebitis and in 1899 Austrian pathologist Hans Chiari, added the first pathologic description of a liver with obliterating endophlebitis of the hepatic veins. The prevalence of Budd-Chiari syndrome is 1/100,000 among the general population worldwide. Compared to adults, it is very uncommon in children. Most of the cases of classic Budd-Chiari syndrome occur between the ages of 20 and 39 years and only 5% were found to be below 12 years of age. The syndrome can be classified as: a) Primary (intra-luminal obstruction by a thrombus or web) or b) secondary (extrinsic compression by an abscess, tumor, cyst, or hyperplastic nodules). Clinically, it can be presented as a) Acute- develops usually within 1 month or symptomatic for less than 6 months and characterized by intractable ascites, abdominal pain, liver enlargement, renal failure, elevation of hepatic enzymes and coagulopathy; b) Subacute- which is insidious onset. It may take as long as 3 months to become asymptomatic, usually having minimal/trace or no ascites but do not have esophageal bleeding; c) Chronic- disease duration of 6 or more months or signs of portal hypertension present. For diagnostic evaluation of Budd-Chiari syndrome, the first step is the doppler ultrasonography of the hepatic vessels and inferior vena cava, which in 95% cases establish the diagnosis. In doppler ultrasonography, highly specific findings for Budd-Chiari syndrome are stenosis, thrombosis, fibrotic cord, or insufficient recanalization of the vessel in the hepatic or caval veins, along with caudate lobe hypertrophy. lab values:

| Parameters                        | Findings | References |
|----------------------------------|----------|------------|
| Total white blood cell count (/mm³) | 6,500    | 4,500-11,000 |
| **Differential count**          |          |            |
| Neutrophil (%)                   | 44       | 40-80      |
| Lymphocyte (%)                   | 49       | 20-40      |
| Platelet (/mm³)                  | 136,000  | 150,000-400,000 |
| Erythrocyte sedimentation rate (mm in first hour) | 40       | 0-10       |
| Hemoglobin (g/dL)                | 11.4     | 13-17      |
| Serum albumin (g/L)              | 41       | 35-50      |
| Prothrombin time (sec)           | 14.8     | 12-16      |
| International normalized ratio   | 1.25     | <1.4       |
| Serum alanine aminotransferase (U/L) | 9        | 35-50      |
| Serum creatinine (mg/dL)         | 0.52     | 0.9-1.3    |
| **Ascitic fluid study**          |          |            |
| Color                            | Straw    |            |
| Total white blood cell count (/mm³) | 160     |            |
| **Differential count**          |          |            |
| Neutrophil (%)                   | 10       |            |
| Lymphocyte (%)                   | 90       |            |
| Total protein (g/L)              | 55       |            |
| Ascitic fluid albumin (g/L)      | 26       |            |
| Glucose (g/L)                    | 5.3      |            |
| Adenosine deaminase (U/L)        | 13.1     | <24        |
| Protein C (%)                    | 83       | 70-140     |
| Protein S (%)                    | 60       | 70-140     |
| Antithrombin III (%)             | 72       | 80-120     |
lymph nodes and solid viscera. In children, the number of extra-pulmonary tuberculosis cases is higher compared to pulmonary tuberculosis. It is difficult to diagnose childhood tuberculosis because of non-specific clinical findings as well as low-quality of sampling, paucibacillary and lack of Mycobacterium culture facilities. Tuberculous bacilli can spread into the abdomen and gastro-intestinal tract by the following route: a) hematogenous spread from the lung focus, b) ingestion of bacilli from the infected sputum, c) unpasturized cow’s milk ingestion, and d) direct spread from adjacent infected structures. Anorexia, malaise, low grade fever, weight loss and abdominal distension due to ascites are the non-specific symptoms of abdominal tuberculosis. Physical examinations may reveal cachexia, fever, lymphadenopathy, absent BCG marks, hepatomegaly, splenomegaly, ascites and features of intestinal obstruction.

Dr. Khondaker Mobasher (Resident): After evaluating the patient’s presenting features, physical findings as patient having no stigmata of chronic liver disease and the liver function tests showed serum albumin (41 g/L), prothrombin time (14.8 sec), normal alanine aminotransferase level (9 U/L) and ultrasonography of the abdomen showed hepatosplenomegaly and huge ascites but hepatic architecture was normal. So, chronic liver disease was excluded.

Our patient was presented with ascites and hepatosplenomegaly which are suggestive but no history of cow’s milk ingestion, no contact history with tuberculosis patient, absence of growth failure and no lymphadenopathy go against the diagnosis of disseminated abdominal tuberculosis. To reach the other differential (abdominal tuberculosis), we did complete blood count, ascitic fluid study, serum ascites albumin gradient, Monteux test and chest X-ray which were normal. So, abdominal tuberculosis was also excluded.

Prof. A. K. M. Fazlul Bari: To establish our provisional diagnosis, we do the color doppler study of portal vein, hepatic veins and inferior vena cava which showed middle hepatic vein was compressed due to enlarged caudate lobe, loss of normal flow characteristics, hepatofugal flow direction along with caudate lobe hypertrophy and features of mild portal hypertension but no thrombosis was found.

Dr. Hassan: According to the color doppler study, we finally diagnosed it as a case of Budd-Chiari syndrome. To find out the cause as well as site of thrombosis, we do the computer tomography venogram of the liver revealed portal vein was dilated, tortuous and produces varices along with the splenoportal circulation. Blood for inherited deficiency revealed deficiency of protein S (60%) and antithrombin III (72%) but protein C (83%) was normal. We also did the endoscopy of upper gastrointestinal tract which revealed developing esophageal varices.

Dr. Hasan’s Diagnosis

Chronic Budd-Chiari syndrome due to inherited thrombophilia (deficiency of protein S and antithrombin III)
Discussion

The child was treated with diuretics and therapeutic paracentesis.

Dr. Fahmida Begum (Associate Professor): Hepatic venous outflow tract obstruction is another synonym of Budd-Chiari syndrome. In our case, hepatic venous flow was obstructed due to compression of middle hepatic vein by caudate lobe. Disease manifestation of our case was started since two years of his age.

In Budd-Chiari syndrome portal vein and hepatic sinusoidal pressures increases because of the stagnation of blood flow due to the obstruction of hepatic venous outflow tract from the venules to the right atrium. Portal pressure increases gradually and thus perfusion of the liver via portal vein is decreased, resulting in liver congestion, right upper quadrant pain and ascites. In both the acute and chronic forms, obstruction leads to centrilobular necrosis and peripheral lobular fatty change due to hypoxic damage of hepatocytes followed by ischemia. If this condition persists a long time during disease progressive fibrosis, nodular regenerative hyperplasia, and ultimately may develop cirrhosis and portal hypertension.

The caudate lobe, which has direct venous drainage into the inferior vena cava, often undergoes compensatory hypertrophy, causes inferior vena cava stenosis. In this case, features of portal hypertension were found by upper gastrointestinal endoscopy and also disease duration for more than 6 months, so it is a chronic case of Budd-Chiari syndrome.

Dr. Md. Wahidduzzaman Mazumder (Associate Professor): Budd-Chiari syndrome may be fulminating (5%), acute (20%), subacute or chronic (60%) and may be asymptomatic (15–20%) of cases approximately. It most often presents as chronic obstruction with abdominal distension, hepatomegaly, ascites and abdominal pain. Other clinical manifestations may be jaundice, upper gastrointestinal bleeding, splenomegaly, distended veins, edema and hepatic encephalopathy. Serum aminotransferase and bilirubin levels are only minimally to moderately elevate usually but also may be normal. Our patient had gradual abdominal distension, occasional abdominal pain, hepatosplenomegaly, ascites and liver function test was normal. Histological finding of veno-occlusive disease, chronic passive congestion and chronic Budd-Chiari syndrome is indistinguishable by microscopy. Acute Budd-Chiari syndrome can present with similar clinical findings but usually present with intractable ascites, abdominal pain, hepatomegaly, renal failure, the elevation of hepatic enzymes and coagulopathy. Our case had ascites, hepatomegaly and occasional abdominal pain since 2 years of life which are the classical presentation of Budd-Chiari syndrome.

Presence of some condition like: a) Abrupt onset of ascites and painful hepatomegaly; b) massive ascites with relatively preserved liver functions; c) sinusoidal dilatation in liver biopsy without heart disease; d) fulminant hepatic failure associated with hepatomegaly and ascites; e) unexplained chronic liver disease; and f) liver disease with thrombogenic disorder when present, Budd-Chiari syndrome should be suspected. Our patient had massive ascites with preserved hepatic function.

The highly specific investigation for Budd-Chiari syndrome is doppler ultrasonography of hepatic vessels and inferior vena cava and it is the first step in evaluation to find out hepatic venous outflow obstruction. Stenosis, thrombosis, fibrotic cord or insufficient recanalization of the hepatic or caval vessel along with caudate lobe hypertrophy in doppler ultrasonography are highly specific for Budd–Chiari syndrome. Caudate lobe hypertrophy usually causes extrinsic compression of the inferior vena cava but this finding is less common in children than the adult. Other imaging findings include no flow signal and with spider-web appearance in hepatic veins, hepatic venous collateral circulation and stagnant, reversed or turbulent flow.

No visualization of hepatic veins or tortuosity is non-specific but most common sonographic findings of Budd–Chiari syndrome. In our case color doppler study showed middle hepatic vein compressed due to enlarged caudate lobe, loss of normal flow characteristics, hepatofugal flow direction and features of mild portal hypertension indicating Budd-Chiari syndrome but no thrombosis in hepatic outflow was found.

Magnetic resonance imaging, computer tomography scan, magnetic resonance angiography, hepatic venography are other second-line imaging modalities which are required to find out any thrombosis and its exact location. Spider-web pattern on hepatic venography or presence of obstacle or its consequences, the collaterals to hepatic veins or inferior vena cava is diagnostic of Budd-Chiari syndrome. In our patient, computer tomography scan of hepatic vessels revealed portal vein is dilated, tortuous and produces varices along with the spleno-portal circulation but no thrombosis was found. When these investigations failed to demonstrate the site of obstruction or any thrombosis then these patients need hepatic/inferior vena cava angiography for confirmation of hepatic venous/inferior vena cava obstruction site or presence of thrombus. In our case, we could not do hepatic/inferior vena cava angiogram due to refusal of the patient party for financial constraint.

Serum bilirubin, aminotransferase levels, alkaline phosphatase and albumin should be done to see hepatic function. Histological findings by liver biopsy of Budd-Chiari syndrome are congestion,
liver cell loss and fibrosis predominantly located in the centrilobular area. Liver biopsy is important in the differentiation of Budd-Chiari syndrome from veno-occlusive disease but not for a diagnosis. Our patient had a normal liver function and thus we didn't do a liver biopsy.

For differentiation between Budd-Chiari syndrome and cardiac disorders like tricuspid regurgitation and constrictive pericarditis echocardiography is helpful. To find out the etiology of Budd-Chiari syndrome hemogram, evaluation of peripheral blood, determination of coagulation factors and inhibitors, genetic tests for factor V and prothrombin mutation, determination of anti-phospholipid antibody, lupus anticoagulant and flow cytometry for paroxysmal nocturnal hemoglobinuria should be performed. For the diagnosis of primary myeloproliferative disorder and determination of total red cell mass bone marrow biopsy may be helpful. Our patient had normal hemogram, echocardiography and we found a deficiency of protein S and antithrombin III. So, the patient is on hypercoagulable state due to inherited thrombophilia.

Dr. Hassan: The therapeutic algorithm for Budd-Chiari syndrome is supportive, medical management of complications, surgical management and liver transplantation. It depends on the chronicity and site of the obstruction, the degree of liver dysfunction in children. Medical, surgical and endovascular therapeutic are options for the treatment of this condition. Initial medical therapy is conservative emphasizing diuretics, therapeutic paracentesis, treatment of predisposing factors, control of portal hypertension and prophylactic anticoagulation to decrease the risk of additional thrombosis. Inferior vena caval reconstruction with a pericardial patch, portosystemic shunts, mesoportal shunts, portoatrial shunts, membrane resection and liver transplantation are the surgical options. Liver transplantation is an appropriate option in patients with long-standing obstruction, having evidence of severe portal hypertension or symptomatic for less than 6 months and chronic liver disease may occur. It depends on the chronicity of severe portal hypertension present so liver transplantation is definitive treatment option. Liver transplantation is needed when medical treatment fails.

Dr. Benzamin (Resident): To exclude cardiac disorders like constrictive pericarditis, right heart failure, etc which are not associated with Budd-Chiari syndrome.

Dr. Ranjit Kumar ( Resident): Why did you do echocardiography?

Dr. Dipanwita Saha (Fellowship course): Yes, as this patient had a long-standing obstruction and evidence of severe portal hypertension present so liver transplantation is definitive treatment option.

Dr. Urmi Roy (Resident): Is there any other treatment option?

Dr. Ahmadur Rahman (Resident): Common causes are inherited or acquired hypercoagulable state due to factor V Leiden and prothrombin mutation, deficiency of protein C, protein S and antithrombin-III. In our case, the patient refuses to take warfarin prophylaxis due to its regular monitoring schedule.

Dr. Nahid E-Subha (Fellowship course): Liver transplantation is an appropriate treatment option if medical therapy fails.

Dr. Ranjit Kumar: Why did you do echocardiography?

Dr. Fahmida: Longtime obstruction in the hepatic vein causes centrilobular necrosis and peripheral lobular fatty change due to hypoxic damage of hepatocytes followed by ischemia. If this condition chronically persist progressive fibrosis, nodular regenerative hyperplasia, cirrhosis and portal hypertension may develop during the course of disease and ultimately the development of the chronic liver disease may occur.

Dr. Slarmisth Ghosal (Resident): How will you differentiate acute from chronic Budd-Chiari syndrome clinically?

Dr. Md. Saidul Islam Suman (Resident): Acute Budd-Chiari syndrome develops usually within 1 month or asymptomatic for less than 6 months and chronic with disease duration of 6 or more months or signs of PHT present.

Dr. Rafiqul Islam (Resident): What are the common causes of Budd-Chiari syndrome?

Dr. Ahmadur Rahman (Resident): Common causes are inherited or acquired hypercoagulable state due to factor V Leiden and prothrombin mutation, deficiency of protein C, protein S and antithrombin-III. In our case, the patient refuses to take warfarin prophylaxis due to its regular monitoring schedule.

Dr. Nahid E-Subha (Resident): It may help in the differentiation of Budd-Chiari syndrome from veno-occlusive disease but not for a diagnosis. Congestion, liver cell loss and fibrosis predominantly located in the centrilobular area are findings in liver
biopsy.

Dr. Nazmul Ahmed (Resident): What are the prognostic factors in Budd-Chiari syndrome?

Dr. Ruhina Tasmeen (Resident): Bad prognostic indicators include ascites, encephalopathy, elevated prothrombin time, and altered serum levels of sodium, creatinine, albumin, and bilirubin, cirrhosis and the presence of portal hypertension.

Follow-up

The patient was improved clinically and biochemically after 3 months of treatment and then further treatment continues accordingly.

Final Diagnosis

Chronic Budd-Chiari syndrome due to inherited thrombophilia (deficiency of protein S and antithrombin III)

Acknowledgement

We are grateful to Prof. A. K. M. Fazlul Bari, National Institute of Nuclear Medicine and Applied Science, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh for color doppler examination of hepatic and portal vasculature.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Campbell K. Systemic disease and the liver. In: Liver disease in children. Suchy FJ, Sokol RJ, Ballisteri WF (eds). 4th ed. Cambridge, Cambridge University Press, 2014, pp 694-99.

2. Kathuriria R, Srivastava A, Surender K, Yachhää SK, Poddar U. Budd-Chiari syndrome in children: Clinical features, percutaneous radiological intervention, and outcome. Eur J Gastroenterol Hepatol. 2014; 26: 1030-38.

3. Aydinli M, Bayraktar Y. Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis. World J Gastroenterol. 2007; 13: 2693-96.

4. Zanetto A, Pellone M, Senzolo M. Milestones in the discovery of Budd-Chiari syndrome. Liver Int. 2019; 39: 1180-85.

5. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: Consensus and controversies. Hepatology 2003; 38: 793-803.

6. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009; 49: 1729-64.

7. Shin N, Kim YH, Xu H, Shi HB, Zhang QQ, Colon Pons JP. Redefining Budd-Chiari syndrome: A systematic review. World J Hepatol. 2016; 8: 691-702.

8. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: A review by an expert panel. J Hepatol. 2003; 38: 364-71.

9. Valla DC. Hepatic vein thrombosis (Budd-Chiari syndrome). Semin Liver Dis. 2002; 22: 5-14.

10. Hector F, George B, Jorge L. Budd-Chiari syndrome. American J Roentgenol. 2012; 199: 737-45.

11. Dilawari JR, Bambery P, Chawla Y, Kaur U, Bhushanmah SR, Malhotra HS. Hepatic outflow obstruction (Budd-Chiari syndrome): Experience with 177 patients and a review of the literature. Medicine 1994; 73: 21-36.

12. Boozari B, Bahr MJ, Kubicka S. Ultrasonography in patients with Budd-Chiari syndrome: Diagnostic signs and prognostic implications. J Hepatol. 2008; 49: 572-80.

13. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-49.

14. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011; 25: 195-206.

15. Shepherd RW, Ramm GA. Fibrogenesis and cirrhosis. In: Walker’s Pediatric gastrointestinal disease. 6th ed. North Carolina, People’s Medical Publishing House, 2018, pp 2984-3025.

16. Chen WS, Leu SY, Lin JK, Lin TC. Trend of large bowel tuberculosis and relation with pulmonary tuberculosis. Dis Colon Rectum. 1992; 35: 189-92.

17. Kabia O, Kara M, Odaclar CA, Kamer I, Sütçu M, Demir SO, Çalışkan E, Törün SH, Salman N, Somer A. Evaluation of cases of pediatric extrapulmonary tuberculosis: A single center experience. Turk Pediatri Ars. 2019; 54: 86-92.

18. Islam Z, Sanin KI, Ahmed T. Improving case detection of tuberculosis among children in Bangladesh: Lessons learned through an implementation research. BMC Public Health, 2017; 17: 131.

19. M Ismail, G Azam. Abdominal tuberculosis. Med Today. 2016; 28: 39-45.

20. Rahman MM, Ahman, Haque KM, Siddiqui MM, Parvin T, Ahmed MK. Budd-Chiari Syndrome: A case report. Univ Heart J. 2007; 3: 80-82.

21. Mahmoud AE, Helmy AS, Billingham L, Elias E. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol. 1997; 9: 485-89.
22. Senzolo M, Cholongitas EC, Patch D, Burroughs AK. Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol. 2005; 2: 182-90.

23. Naomi S, Young H, Hao X, Yi X, Fei-Yun W, Samuel H, Byung-Boong L, Lin-Sun Li. Redefining Budd-Chiari syndrome: A systematic review. World J Hepatol. 2016; 8: 691-702.

24. Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004; 350: 578-85.

25. Amarpurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol. 2008; 14: 278-85.

26. Rajeev R, Anant B, Varun H, Vinod R, Swathi C. Pediatric Budd-Chiari syndrome: A case series. Pediatricrology 2018; 55: 871-77.

27. Acharya J, Westwood NB, Sawyer BM, Messiney M, Burroughs AK, Mehta AB, Pearson TC. Identification of latent myeloproliferative disease in patients with Budd-Chiari syndrome using X-chromosome inactivation patterns and in vitro erythroid colony formation. Eur J Haematol. 1995; 55: 315-21.

28. Klein AS. Management of Budd-Chiari syndrome. Liver Transpl. 2006; 12: 23-28.

29. Garcia-Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, Vizzini G, Abraldes JG, Olliff S, Nicolini A, Luca A. TIPS for Budd-Chiari syndrome: Long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135: 808-15.

30. Murad SD, Valla DC, De Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, Van Hoek B, Hansen BE, Rosendaal FR, Janssen HL. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39: 500-08.